Latest Biotech News

Researchers published integrated methods for simultaneous, multiplexed epigenetic and genetic programming of primary human T cells, showcasing a platform that can stably silence or activate...

Replimune resubmitted a biologics license application for its oncolytic viral therapy RP1 after a July rejection, supplying additional analyses and data to address prior FDA concerns. The agency...

Takeda struck a series of high-value licensing deals with Innovent Biologics, handing over roughly $1.2 billion upfront for rights to two oncology candidates and signaling a major pivot toward...

Electra Therapeutics closed a $183 million Series C to fund a pivotal trial of ELA026, its monoclonal antibody for secondary hemophagocytic lymphohistiocytosis (HLH), and to advance a second...

Replimune resubmitted its biologics license application for RP1, an engineered oncolytic herpesvirus given with checkpoint inhibition, and the FDA accepted the filing — triggering a near-doubling...

Flagship Pioneering unveiled Expedition (also called Expedition Medicines), an AI-driven drug discovery company seeded with $50 million and an early collaboration with Pfizer to target cancer and...

Private-equity firms Blackstone and TPG agreed to acquire Hologic for $76 a share, plus up to $3 in contingent payments, valuing the diagnostic and med‑tech firm at as much as $18.3 billion. The...

Grail secured $325 million in a private placement to bolster its balance sheet ahead of regulatory filings for its multi‑cancer blood test. The company also released Pathfinder 2 data showing...

Sanofi signed a collaboration and license agreement with Evoq Therapeutics, gaining rights to Evoq’s NanoDisc dendritic cell technology in exchange for up to $500 million in milestones. Sanofi...

GSK and Spero Therapeutics reported Phase 3 non‑inferiority results for tebipenem HBr versus the standard of care, validating the oral antibiotic’s potential to match IV therapy and prompting...

10x Genomics filed patent litigation against Illumina in Delaware federal court, alleging infringement tied to single‑cell and spatial transcriptomics technologies as the two firms intensify...

Galapagos announced it could not find a buyer for its cell therapy unit and will wind down the business, a decision that will lead to the closure of facilities in Europe, China and the U.S. and...

Sanofi struck a collaboration and licensing deal with Evoq Therapeutics that could deliver more than $500 million in milestone payments tied to preclinical, development and sales targets, giving...

Hologic agreed to be acquired by funds led by Blackstone and TPG in a transaction valued up to $18.3 billion, including contingent value rights tied to breast-health revenue targets. The board...

Replimune announced that the FDA accepted a resubmitted biologics license application for RP1, an oncolytic HSV‑based therapy given with PD‑1 blockade, setting a new decision date in April 2026....

Exelixis plans an NDA submission for zanzalintinib after detailed Stellar‑303 Phase III results showed an overall survival benefit when the oral TKI was combined with atezolizumab versus...

An international, multicenter study reported at ESMO and in associated publications that circulating tumor DNA (ctDNA) testing can stratify recurrence risk after surgery for muscle‑invasive...

Cancer‑screening firm Grail announced a $325 million private placement to fund commercial expansion, reimbursement push and working capital for its multi‑cancer detection Galleri blood test. The...

10x Genomics filed two patent infringement suits against Illumina in Delaware federal court, alleging the sequencing giant infringed intellectual property tied to single‑cell and spatial...

Danaher’s Integrated DNA Technologies (IDT) announced a collaboration with Profluent Bio to use Profluent’s ProGen3 foundation model for AI‑driven enzyme design, combining IDT’s enzymology and...